Combating increased antifungal drug resistance in Cryptococcus, what should we do in the future?
Authors:
- 22 February 2023
- journal article
- review article
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 55 (4) , 540-547
Abstract
Few therapeutic drugs and increased drug resistance have aggravated the current treatment difficulties of Cryptococcus in recent years. To better understand the antifungal drug resistance mechanism and treatment strategy of cryptococcosis. In this review, by combining the fundamental features of Cryptococcus reproduction leading to changes in its genome, we review recent research into the mechanism of four current anti-cryptococcal agents, coupled with new therapeutic strategies and the application of advanced technologies WGS and CRISPR-Cas9 in this field, hoping to provide a broad idea for the future clinical therapy of cryptococcosis.Keywords
This publication has 80 references indexed in Scilit:
- Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin BPLOS Biology, 2013
- Unisexual and Heterosexual Meiotic Reproduction Generate Aneuploidy and Phenotypic Diversity De Novo in the Yeast Cryptococcus neoformansPLOS Biology, 2013
- Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalJournal of Antimicrobial Chemotherapy, 2013
- Characterization of the Chromosome 4 Genes That Affect Fluconazole-Induced Disomy Formation in Cryptococcus neoformansPLOS ONE, 2012
- Identification of a Cryptococcus neoformans Cytochrome P450 Lanosterol 14α-Demethylase (Erg11) Residue Critical for Differential Susceptibility between Fluconazole/Voriconazole and Itraconazole/PosaconazoleAntimicrobial Agents and Chemotherapy, 2012
- Amphotericin primarily kills yeast by simply binding ergosterolProceedings of the National Academy of Sciences, 2012
- A Flucytosine-Responsive Mbp1/Swi4-Like Protein, Mbs1, Plays Pleiotropic Roles in Antifungal Drug Resistance, Stress Response, and Virulence of Cryptococcus neoformansEukaryotic Cell, 2012
- Hrk1 Plays Both Hog1-Dependent and -Independent Roles in Controlling Stress Response and Antifungal Drug Resistance in Cryptococcus neoformansPLOS ONE, 2011
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Identification and Characterization ofCPS1as a Hyaluronic Acid Synthase Contributing to the Pathogenesis ofCryptococcus neoformansInfectionEukaryotic Cell, 2007